Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Common Equity (2017 - 2025)

Catheter Precision has reported Common Equity over the past 9 years, most recently at $7.1 million for Q4 2025.

  • Quarterly Common Equity fell 40.0% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, down 40.0% year-over-year, with the annual reading at $7.1 million for FY2025, 40.0% down from the prior year.
  • Common Equity was $7.1 million for Q4 2025 at Catheter Precision, up from $6.4 million in the prior quarter.
  • Over five years, Common Equity peaked at $35.9 million in Q1 2023 and troughed at $5398.0 in Q3 2023.
  • The 5-year median for Common Equity is $13.2 million (2021), against an average of $14.4 million.
  • Year-over-year, Common Equity plummeted 99.96% in 2023 and then surged 237506.52% in 2024.
  • A 5-year view of Common Equity shows it stood at $13.7 million in 2021, then plummeted by 32.28% to $9.3 million in 2022, then surged by 128.87% to $21.2 million in 2023, then tumbled by 44.52% to $11.8 million in 2024, then crashed by 40.0% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for VTAK's Common Equity are $7.1 million (Q4 2025), $6.4 million (Q3 2025), and $6.5 million (Q2 2025).